menu
    • menu
    [{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glycerine","moa":"Glutamine","graph1":"Dermatology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"Glutamine","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Dalhousie University","highestDevelopmentStatusID":"6","companyTruncated":"Nova Scotia Health Authority \/ Dalhousie University"},{"orgOrder":0,"company":"McMaster University","sponsor":"McMaster Surgical Associates | Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; Adenine DNA glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suppository","sponsorNew":"McMaster University \/ McMaster Surgical Associates | Hamilton Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ McMaster Surgical Associates | Hamilton Health Sciences"},{"orgOrder":0,"company":"Calm Water Therapeutics","sponsor":"Andover Research Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; Adenine DNA glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Calm Water Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calm Water Therapeutics \/ Andover Research Eye Institute","highestDevelopmentStatusID":"1","companyTruncated":"Calm Water Therapeutics \/ Andover Research Eye Institute"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; Adenine DNA glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Rochester \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"6","companyTruncated":"University of Rochester \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylga","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"||PPA receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Curcuma Longa","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for MolPort-001-785-853

    Menu

    MolPort-001-785-853

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bausch & Lomb Incorporated

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bausch + Lomb Launches Blink Nourish & Blink Boost Eye Drops in US

                            Details : Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film.

                            Product Name : Blink Nourish

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 04, 2025

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alcon Inc

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins

                            Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                            Product Name : Tears Naturale Forte

                            Product Type : Carbohydrate

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shilpa Medicare

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shilpa Medicare

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcuma Longa,Glycerine,Propolis

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shilpa Medicare Launches 'Oraal’ for Treatment of Oral Mucositis

                            Details : ORAAL, an oral spray with a naturally derived formulation, which is indicated for the treatment of oral mucositis. The composition of ORAAL is protected by a granted patent in India until November 2033.

                            Product Name : Oraal

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2023

                            Lead Product(s) : Curcuma Longa,Glycerine,Propolis

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calm Water Therapeutics

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Calm Water Therapeutics

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Andover Research Eye Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

                            Details : Glycerin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 21, 2022

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Andover Research Eye Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Santen Pharmaceutical

                            Japan arrow
                            AllPack Indonesia
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine,Poloxamer,Tyloxapol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular All...

                            Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...

                            Product Name : Cationorm Plus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : Glycerine,Poloxamer,Tyloxapol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nova Scotia Health Authority

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed

                            Nova Scotia Health Authority

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Dalhousie University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear

                            Details : Glycerol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tympanosclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 11, 2022

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Dalhousie University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            McMaster University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            McMaster University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : McMaster Surgical Associates | Hamilton Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlle...

                            Details : Glycerin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Feeding and Eating Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 03, 2014

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : McMaster Surgical Associates | Hamilton Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pierre Fabre

                            France arrow
                            AllPack Indonesia
                            Not Confirmed

                            Pierre Fabre

                            France arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emollients in the Management of Atopic Dermatitis

                            Details : Glycerol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2013

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Rochester

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            University of Rochester

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Objective Evaluation of Ocular Surface Lubricants in Two Environments

                            Details : Glycerin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2011

                            Lead Product(s) : Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth